Matej Kastelic / Shutterstock.com
Introduced in September 2012, the inter partes review provided a new forum for challenging the validity of US patents, and soon attracted criticism. WIPR investigates how life sciences companies have fared in the forum’s first four years.
Signed into law in September 2011, the America Invents Act introduced new procedures for challenging patent validity at the US Patent and Trademark Office (USPTO).
The following September, one of those procedures—the inter partes review (IPR)—became available, allowing any person to challenge a patent by filing a petition before a panel of administrative judges at the Patent Trial and Appeal Board (PTAB).
In 2013, Randall Rader, the former chief judge of the US Court of Appeals for the Federal Circuit, called the PTAB a “death squad” for patents.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
America Invents Act, inter partes review, US Patent and Trademark Office, PTAB, life sciences, Shire, Lialda,